Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Novartis
Shattuck Labs, Inc.
Takeda
Novartis
Hackensack Meridian Health
St. Jude Children's Research Hospital
Orca Biosystems, Inc.
National Cancer Institute (NCI)
Roswell Park Cancer Institute
Gamida Cell ltd
City of Hope Medical Center
Dartmouth-Hitchcock Medical Center
NextCure, Inc.
University of Rochester
M.D. Anderson Cancer Center
Brown University
Novartis
Masonic Cancer Center, University of Minnesota
Geron Corporation
Montefiore Medical Center
M.D. Anderson Cancer Center
Masonic Cancer Center, University of Minnesota
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
Dana-Farber Cancer Institute
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Incyte Corporation
City of Hope Medical Center
City of Hope Medical Center
Novartis
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Thomas Jefferson University
Baylor College of Medicine
Incyte Corporation
Takeda
Incyte Corporation
Incyte Corporation
Incyte Corporation